Xiao ChenKapolei, HI

6436928, Aug 20, 2002

Dec 14, 2000

09/737036

Neng-Yang Shih - North Caldwell NJ
Gregory A. Reichard - Morris Plains NJ
Sunil Paliwal - Scotch Plains NJ
David J. Blythin - North Caldwell NJ
John J. Piwinski - Clinton Township NJ
Dong Xiao - Scotch Plains NJ
Xiao Chen - Edison NJ

Schering Corporation - Kenilworth NJ

A61K 314166

5142278, 514396, 514399, 514400, 5483165, 5483235

A compound represented by the structural formula or a pharmaceutically acceptable salt thereof, wherein Ar and Ar are optionally substituted heteroaryl or optionally substituted phenyl; X is âOâ, âSO â, âNR â, âNCOR â or âNR SO R ; âis X is âOâ, âSâ or optionally substituted nitrogen; Y is O, S or NR ; Y is H, alkyl, âNR R , âSCH , R -aryl(CH ) â, R -heteroaryl-(CH ) â, â(CH ) -heterocycloalkyl, -alkyl-NHâC(O)O-alkyl or âNHC(O)R ; R , R , R and R are H, alkyl, OH-alkyl, cycloalkyl, âCHF , âCH F or âCF ; or R and R form an alkylene ring; or R and R together are O; R is H, alkyl, âOR or âSR ; and the remaining variables are as defined in the specification, is disclosed, as well as a pharmaceutical compositions comprising said compound, methods of using said compound as a neurokinin antagonist, and the combination of said compounds with a selective serotonin reuptake inhibitor.

6635630, Oct 21, 2003

Jun 6, 2002

10/163663

Neng-Yang Shih - North Caldwell NJ
Gregory A. Reichard - Morris Plains NJ
Sunil Paliwal - Scotch Plains NJ
David J. Blythin - North Caldwell NJ
John J. Piwinski - Clinton Township NJ
Dong Xiao - Scotch Plains NJ
Xiao Chen - Edison NJ

Schering Corporation - Kenilworth NJ

A61K 31330

514183, 514396, 514397, 514398, 514400, 5483235, 5483215, 5483251, 5483255, 5483265, 548134

Compound represented by the structural formula or a pharmaceutically acceptable salt thereof, wherein Ar and Ar are optionally substituted heteroaryl or optionally substituted phenyl; X is âOâ, âSâ, âSOâ, âSO â, âNR â, âNCOR â or âNR SO R ; âis selected from the group consisting of X is âOâ, âSâ or âNR â; Y is O, S or NR ; Y is H, C -C alkyl, âNR R , âSCH , R -aryl(CH ) â, R -heteroaryl-(CH ) â, â(CH ) âheterocycloalkyl, â(C -C )alkyl-NHâC(O)O(C -C )alkyl or âNHC(O)R ; R is H or â(CH ) âG, wherein n is 0-5, G is H, âCF , âCHF , âCH F, âOH, âOâ(C -C alkyl), âSO R , âOâ(C -C cycloalkyl), âNR R , âSO NR R , âNR SO R , âNR COR , âNR (CONR R ), âCONR R , âCOOR , C -C cycloalkyl, R -aryl, R -heteroaryl, and provided when n =0, G is not H; R , R , R and R are H, alkyl, cycloalkyl, âCHF , âCH F or âCF ; or R and R , together with the carbon to which they are attached, form an alkylene ring; or R and R together are O; R is R or âOH; and the remaining variables are as defined in the specification, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds, and pharmaceutical compositions comprising said compounds are disclosed. Also disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and in combination with an effective amount of a selective serotonin reuptake inhibitor.

6720329, Apr 13, 2004

Mar 12, 2002

10/096804

Gregory R. Ott - Media PA
Xiao Tao Chen - Newark DE
Jingwu Duan - Newark DE
Matthew E. Voss - Lincoln University PA

Bristol-Myers Squibb Pharma - Princeton NJ

A61K 31443

514278, 514342, 514339, 514336, 546 15, 546152, 5462681, 5462764, 5462797, 5462817

The present application describes novel spiro-cyclic -amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF- converting enzyme (TACE), and/or aggrecanase inhibitors.

6962938, Nov 8, 2005

Dec 18, 2003

10/741326

Gregory R. Ott - Media PA, US
Xiao Tao Chen - Furlong PA, US
Jingwu Duan - Yardley PA, US
Matthew E. Voss - Lincoln University PA, US

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61K031/403
A61K031/38
C07D327/04
C07D207/04
C07D207/18

514409, 514438, 514462, 549 30, 549200, 549300, 549322, 549337, 549341, 548407

The present application describes novel spiro-cyclic β-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), and/or aggrecanase inhibitors.

7160856, Jan 9, 2007

Jul 25, 2002

10/205021

Samuel J. Danishefsky - Englewood NJ, US
Dalibor Sames - New York NY, US
Samuel Hintermann - Basel, CH
Xiao Tao Chen - Newark DE, US
Jacob B. Schwarz - Ann Arbor MI, US
Peter Glunz - Wilmington DE, US
Philip O. Livingston - New York NY, US
Scott Kuduk - Harleyville PA, US
Lawrence Williams - New York NY, US

Sloan-Kettering Institute for Cancer Research - New York NY

A61K 38/14
A61K 39/385
C07K 9/00

514 8, 4241851, 4241941, 4242771, 530322

The present invention provides novel α-O-linked glycoconjugates such as α-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the α-O-linked glycoconjugates.

7956189, Jun 7, 2011

Aug 10, 2007

11/891351

Xiaoming Chen - Westfield NJ, US
Xiao Chen - Edison NJ, US
Jianguo Yin - Plainsboro NJ, US
Xiaoyong Fu - Edison NJ, US
David J. Blythin - North Caldwell NJ, US
Rongze Kuang - Green Brook NJ, US
Scott Trzaska - Raritan NJ, US
Chee-Wah Tang - Singapore, SG
Vincenzo Liotta - Glen Ridge NJ, US
Zaher Shabani - Budd Lake NJ, US

Schering Corporation - Kenilworth NJ

C07D 215/38

546167

Disclosed are maleate, tosylate, fumarate, and oxalate salts of the compound 5-(1(S)-Amino-2-Hydroxyethyl)-N-[(2,4-Difluorophenyl)-Methyl]-2-[8-Methoxy-2-(Trifluoromethyl)-5-Quinoline]-4-Oxazolecarboxamide, represented by Formula I, and methods of preparing the same.

2004010, May 27, 2004

Jun 19, 2003

10/600012

Samuel Danishefsky - Englewood NJ, US
Dalibor Sames - New York NY, US
Samuel Hintermann - Basel, CH
Xiao Chen - Newark DE, US
Jacob Schwarz - Ann Arbor MI, US
Peter Glunz - Wilmington DE, US
Philip Livingston - New York NY, US
Scott Kuduk - Harleyville PA, US
Kenneth Lloyd - New York NY, US
Lawrence Williams - New York NY, US
Valery Kudryashov - Brooklyn NY, US

C07K009/00
A61K038/14

530/322000, 514/008000

The present invention provides novel -O-linked glycoconjugates such as -O-linked glycopeptides, as well as convergent methods for the synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the -O-linked glycoconjugates.

2013019, Aug 1, 2013

Jan 31, 2013

13/755637

Dennis Yamashita - Wayne PA, US
Xiao Tao Chen - Furlong PA, US

Trevena, Inc. - King of Prussia PA

C07K 7/06

514 37, 530328, 514 217, 514 164

This application describes compounds acting as, for example, β-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.